MMEA
SRPT icon

Main Management ETF Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Main Management ETF Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,597
Closed -$113K – 186
2025
Q2 		$113K Buy
6,597
+108
+2% +$4.61K ﹤0.01% 136
2025
Q1 		$414K Buy
6,489
+1,505
+30% +$158K 0.02% 134
2024
Q4 		$606K Sell
4,984
-448
-8% -$54.9K 0.03% 128
2024
Q3 		$678K Buy
+5,432
New +$751K 0.03% 134

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Main Management ETF Advisors's SRPT Position: Q3 2025 in Review

Main Management ETF Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 6,597 shares — an estimated $113K sold.

Main Management ETF Advisors first reported a position in SRPT in Q3 2024 and held it in 4 quarters. The position peaked at $678K in Q3 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Main Management ETF Advisors reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Main Management ETF Advisors sold 6,597 Sarepta Therapeutics shares in Q3 2025, an estimated $113K.
  • Main Management ETF Advisors first reported a position in Sarepta Therapeutics in Q3 2024 and held it in 4 quarters.
  • Main Management ETF Advisors's Sarepta Therapeutics position peaked at $678K in Q3 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Main Management ETF Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.